Current Drug Targets


Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556

Personal Subscription
Become EABM
Become Reviewer

Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational Gastroenterology Comes of Age) free to download

Volume:14   Issue: 12
Pp: 1377-1378
Silvio Danese and Laurent Peyrin-Biroulet
DOI: 10.2174/13894501113146660220

Anti-IL-12/23 in Crohn's Disease: Bench and Bedside

Volume:14   Issue: 12
Pp: 1379-1384
Lukas Niederreiter, Timon Erik Adolph and Arthur Kaser
DOI: 10.2174/13894501113146660229

Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment

Volume:14   Issue: 12
Pp: 1385-1391
Lucine Vuitton, Stéphane Koch and Laurent Peyrin-Biroulet
DOI: 10.2174/13894501113149990160

Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases

Volume:14   Issue: 12
Pp: 1392-1399
Takanori Kanai, Nobuhiko Kamada and Tadakazu Hisamatsu
DOI: 10.2174/13894501113149990006

TGF-Beta Signaling Manipulation as Potential Therapy for IBD

Volume:14   Issue: 12
Pp: 1400-1404
Irene Marafini, Francesca Zorzi, Sefora Codazza, Francesco Pallone and Giovanni Monteleone
DOI: 10.2174/13894501113149990157

Review: New Anti-Cytokines for IBD: What is in the Pipeline?

Volume:14   Issue: 12
Pp: 1405-1420
Michael Scharl, Stephan R. Vavricka and Gerhard Rogler
DOI: 10.2174/13894501113149990159

Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?

Volume:14   Issue: 12
Pp: 1421-1432
Angelos Oikonomopoulos, Welmoed K. van Deen and Daniel W. Hommes
DOI: 10.2174/13894501113149990164

Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside

Volume:14   Issue: 12
Pp: 1444-1452
Manol Jovani, Gionata Fiorino and Silvio Danese
DOI: 10.2174/13894501113149990170

Cell Therapies for IBD: What Works?

Volume:14   Issue: 12
Pp: 1453-1459
Elena Ricart, Aranzazu Jauregui-Amezaga, Ingrid Ordás, Susana Pinó and Anna M. Ramírez
DOI: 10.2174/13894501113146660234

Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions

Volume:14   Issue: 12
Pp: 1460-1470
Walter Fries, Alessandra Belvedere and Stefania Vetrano
DOI: 10.2174/1389450111314120011

Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?

Volume:14   Issue: 12
Pp: 1471-1479
Anne Bourrier, Philippe Seksik and Jacques Cosnes
DOI: 10.2174/13894501113149990172

Methotrexate: Should We Start Using it in Clinical Practice?

Volume:14   Issue: 12
Pp: 1480-1489
Pal Miheller, Lajos S. Kiss, Michael Mandel and Peter L. Lakatos
DOI: 10.2174/13894501113149990604

Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease

Volume:14   Issue: 12
Pp: 1490-1500
Giorgos Bamias, David J. Clark and Jesús Rivera-Nieves
DOI: 10.2174/13894501113149990158

PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention

Volume:14   Issue: 12
Pp: 1501-1507
Benjamin Bertin, Laurent Dubuquoy, Jean-Frédéric Colombel and Pierre Desreumaux
DOI: 10.2174/13894501113149990162

Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target

Volume:14   Issue: 12
Pp: 1508-1521
Mariangela Allocca, Manol Jovani, Gionata Fiorino, Stefan Schreiber and Silvio Danese
DOI: 10.2174/13894501113146660224